Overall, pAMPK inhibition downstream of high CIP2A may enhance anabolic growth, invasiveness, and therapy resistance in NSCLC, while recognizing AMPK’s context-dependent roles [30,49,51]. This evidence concerns the gene CIP2A and non-small cell lung carcinoma.